Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment

Table 1 Follow-up and baseline ctDNA status of the patients (n = 32)

Patient ID	Clinical relapse	Time to relapse (months)	Site(s) of relapse	Death	Time to death or last follow-up (months)	Baseline ctDNA detection	Baseline ctDNA copies/ml
3	Yes	30	Lung	No	50	No	0.0
4	No	-		No	46	No	0.0
5	Yes	32	LN	Yes	41	Yes	4.2
6	Yes	23	LN, skin	No	46	Yes	1.3
13	No	-		No	45	No	0.0
14	No	-		No	44	Yes	2.0
16	No	-		No	41	No	0.0
17	No	-		Yes	45	No	0.0
18	No	-		No	46	No	0.0
20	Yes	19	LN	No	37	No	0.0
21	Yes	19	Skin	Yes	35	No	0.0
22	No	-		No	37	No	0.0
23	No	-		No	36	No	0.0
24	No	-		No	12²	No	0.0
32	Yes	13	Brain	Yes	13	Yes	3.2
36	No	-		No	43	Yes	6.3
37	No	-		No	37	No	0.0
40	No	-		No	38	No	0.0
41	No	-		No	41	Yes	7.2
42	Yes	5	LN, lung, liver	Yes	6	Yes	2.7
47	Yes	9	Brain	Yes	15	Yes	6.8
49	No	-		No	35	No	0.0
56	Yes	22	Widespread disease¹	No	48	No	0.0
59	Yes	3	Brain	Yes	24	Yes	1.8
61	Yes	20	LN	No	42	No	0.0
69	No	-		No	37	No	0.0
74	No	-		No	40	No	0.0
75	No	-		No	37	No	0.0
77	No	-		No	43	Yes	2.6
80	No	-		No	35	No	0.0
82	No	-		No	35	No	0.0
85	Yes	9	Brain	Yes	10	Yes	3.3

Abbreviations: LN, lymph node; ctDNA, circulating tumor DNA
¹patient with metastases in multiple sites: LN, lung, skin, liver, spleen, and adrenal gland. ² The patient was lost at the follow-up

ISSN: 1479-5876